CVE-2026-33076 json
Roxy-WI vulnerable to path traversal and arbitrary file writing
published 2026-04-24 6 mo ago modified 2026-06-17 4 mo ago also EUVD-2026-25375
- cvss
- 9.8
- version 3.1, NVD
- cisa kev
- Not listed
- not in CISA's catalog
- epss
- 0.8%
- EPSS 0.8% chance of exploitation in 30 days, percentile 57%
- public exploits
- 0
- none known
Summary
Roxy-WI is a web interface for managing Haproxy, Nginx, Apache and Keepalived servers. Prior to version 8.2.6.4, the haproxy_section_save interface presents a vulnerability that could lead to remote code execution due to path traversal and writing into scheduled tasks. Version 8.2.6.4 fixes the issue.
Patch / fix
CISA SSVC
- Exploitation
- Proof of concept is public
- Automatable
- yes
- Technical impact
- total
- Assessed
- 6 mo ago
Exploit prediction
0.82% chance of exploitation in the next 30 days, higher than 57% of all scored CVEs (FIRST EPSS, 2026-11-08).
Exploits and checks
- github.com https://github.com/roxy-wi/roxy-wi/security/advisories/GHSA-mmgm-p9x9-h33j referenced PoC, tagged "exploit" by a source, unverified
CVSS scores
| assigned by | version | score | vector |
|---|---|---|---|
| CNA | 4.0 | 8.9 | CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P |
| CNA | 4.0 | 8.9 | CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X |
| NVD | 3.1 | 9.8 | CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H |
Affected products
- roxy-wi roxy-wi
Classification
- Weakness
-
- CWE-22 Improper Limitation of a Pathname to a Restricted Directory
References
Sources
- CVE List CVE-2026-33076
- NVD CVE-2026-33076
Fencer Vulns keeps one entry per vulnerability: the CVE id wins, then GHSA, and records that alias each other are merged, except that two CVEs always keep separate entries. The same data is available as JSON.
CPEs and fixed versions use Anchore's correction of NVD's data: Added CPE configurations because not yet analyzed by NVD.